23andMe Continuing GWAS into Disease Factors; Official 'Optimistic' Over FDA Talks | GenomeWeb

By Tony Fong

SAN FRANCISCO (GenomeWeb News) – Genetic testing firm 23andMe is continuing to leverage its database of patients using its tests to perform additional research, its senior director of research said Tuesday.

At the annual Burrill Personalized Medicine Meeting here, Joanna Mountain told audience members that the Mountain View, Calif., company is currently preparing studies in three areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.